Intensive statin therapy in acute coronary syndromes

Current Atherosclerosis Reports

Volumn 10, Issue 2, 2008, Pages 158-163

  Liew, Tze Vun ^b   Ray, Kausik K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CLOPIDOGREL; COLLAGEN; ELASTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; PLEIOTROPY; REVIEW; RISK FACTOR; RISK REDUCTION; THROMBOCYTE FUNCTION; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VASCULAR SMOOTH MUSCLE;

ACUTE CORONARY SYNDROME; BLOOD PLATELETS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; SIMVASTATIN;

EID: 41749111163     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0023-1     Document Type: Review

References (50)

1. Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
2. Hospital Episode Statistics 2004-2005. Available at http://www.hesonlinenhsuk2006. Accessed October 10, 2007.
3. Naghavi M, Libby P, Falk E, et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003, 108:1772-1778.
4. Naghavi M, Libby P, Falk E, et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
5. Wallentin L, Lagerqvist B, Husted S, et al.: Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000, 356:9-16.
6. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
7. Gordon T, Castelli WP, Hjortland MC, et al.: Predicting coronary heart disease in middle-aged and older persons. The Framington study. JAMA 1977, 238:497-499.
8. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-1357.
11. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440-1445.
12. Collins R, Peto R, Armitage J: The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002, 56:53-56.
13. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
14. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
15. Buchwald H, Varco RL, Boen JR, et al.: Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998, 158:1253-1261.
16. Buchwald H, Varco RL, Marts JP, et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990, 323:946-955.
17. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995, 92:657-671.
18. Chan WL, Pejnovic N, Hamilton H, et al.: Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ Res 2005, 96:675-683.
19. Toutouzas K, Drakopoulou M, Mitropoulos J, et al.: Elevated plaque temperature in non-culprit de novo atheromatous lesions of patients with acute coronary syndromes. J Am Coll Cardiol 2006, 47:301-306.
20. Blake GJ, Ridker PM: C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003, 41(4 Suppl 4):37S-42S.
21. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109(23 Suppl 1):III27-III32.
22. Watanabe N, Ikeda U: Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004, 6:112-120.
23. Haramaki N, Ikeda H, Takenaka K, et al.: Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 2007, 27:1471-1477.
24. Sanguigni V, Pignatelli P, Lenti L, et al.: Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005, 111:412-419.
25. Mitsios JV, Papathanasiou AI, Elisaf M, et al.: The inhibitory potency of clopidogrel on ADP-induccd platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets 2005, 16:287-292.
26. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399-1402.
27. Schonbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004, 109(21 Suppl 1):II18-II26.
28. Ray KK, Cannon CP: The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005, 46:1425-1433.
29. Ray KK, Morrow DA, Shui A, et al.: Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol 2006, 98:861-865.
30. Kinlay S, Schwartz GG, Olsson AG, Rifai N, et al.: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003, 108:1560-1566.
31. Link A, Ayadhi T, Bohm M, Nickenig G: Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006, 27:2945-2955.
32. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
33. Beckman JA, Creager MA: The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med 2006, 16:156-162.
34. Dilaveris P, Giannopoulos G, Riga M, et al.: Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007, 5:227-237.
35. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al.: Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006, 27:1182-1190.
36. Hosokawa S, Hiasa Y, Tomokane T, et al.: The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction. Clin Cardiol 2006, 29:357-362.
37. Furman C, Copin C, Kandoussi M, et al.: Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004, 174:93-98.
38. Luan Z, Chase AJ, Newby AC: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003, 23:769-775.
39. Spencer FA, Allegrone J, Goldberg RJ, et al.: Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004, 140:857-866.
40. Fonarow GC, Wright RS, Spencer FA, et al.: Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005, 96:611-616.
41. Liem AH, van Boven AJ, Veeger NJ, et al.: Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002, 23:1931-1937.
42. Thompson PL, Meredith I, Amerena J, et al.: Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J 2004, 148:e2.
43. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
44. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
45. Olsson AG, Schwartz GG, Szarek M, et al.: High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005, 26:890-896.
46. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
47. Ray KK, Cannon CP, McCabe CH, et al.: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1405-1410
48. Wiviott SD, de Lemos JA, Cannon CP, et al.: A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006, 113:1406-1414.
49. Ridker PM, Morrow DA, Rose LM, et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/1: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45:1644-1648.
50. Ray KK, Cannon CP, Cairns R, et al.: Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1417-1424.